Enzo Biochem, Inc.
https://www.enzo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Enzo Biochem, Inc.
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Company Information
- Industry
- Biotechnology
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Enzo Life Sciences
- Enzo Clinical Labs